ABBV Company Profile and Key Details

Q: Who are the executives of ABBV?

Mr. Jeffrey Ryan StewartExecutive Vice President & Chief Commercial OfficerMr. Scott T. ReentsExecutive Vice President & Chief Financial OfficerMr. Richard A. GonzalezChairman & Chief Executive OfficerDr. Thomas J. HudsonSenior Vice President of R&D and Chief Scientific OfficerMr. Perry C. SiatisExecutive Vice President, Gen. Counsel & Sec.Mr. Timothy J. RichmondExecutive Vice President & Chief HR OfficerDr. Nicholas R. Donoghoe M.D.Executive Vice President and Chief Bus. & Strategy OfficerDr. Azita Saleki-Gerhardt Ph.D.Executive Vice President & Chief Operating OfficerMs. Rae L. LivingstonChief Equity OfficerMs. Laura J. SchumacherVice Chairman of External Affairs & Chief Legal OfficerDr. Thomas J. Hudson M.D.Senior Vice President of R&D and Chief Scientific OfficerMs. Tracie HaasSenior Vice President of Corporation Responsibility, Brand & CommunicationsDr. Thomas Hudson M.D.Senior Vice President of R&D and Chief Scientific OfficerMs. Carrie C. StromSenior Vice President of AbbVie & Pres of Global Allergan AestheticsMr. Henry O. GosebruchExecutive Vice President & Chief Strategy OfficerMr. Robert A. MichaelPres & Chief Operating OfficerMs. Elizabeth SheaVice President of Investor Relations

NYSE : ABBV

AbbVie

$223.43

4.41+2.01%

At Close 4:00 PM

66.15

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

AbbVie Inc. (ABBV) stock surged +2.01%, trading at $223.43 on NYSE, up from the previous close of $219.02. The stock opened at $218.75, fluctuating between $218.50 and $225.82 in the recent session.

Stock Snapshot

219.02

Prev. Close

394.89B

Market Cap

218.5001

Day Low

94.27

P/E Ratio

2.37

EPS (TTM)

12.49

Cash Flow per Share

218.75

Open

1.77B

Number of Shares

225.82

Day High

99.8%

Free Float in %

5.87

Book Value

5.05M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 06, 2026	218.75	225.82	218.50	223.43	6.04M
Feb 05, 2026	216.90	219.87	214.04	219.02	10.79M
Feb 04, 2026	209.78	220.85	204.27	217.11	15.27M
Feb 03, 2026	223.95	228.70	223.64	225.66	8.15M
Feb 02, 2026	224.85	229.79	224.42	225.64	5.39M
Jan 30, 2026	220.51	224.02	219.56	223.01	6.55M
Jan 29, 2026	218.00	224.14	218.00	220.43	7.79M
Jan 28, 2026	223.60	224.03	216.70	218.67	4.99M
Jan 27, 2026	220.88	226.86	220.65	223.93	5.64M
Jan 26, 2026	219.11	221.48	218.50	220.77	6.55M
Jan 23, 2026	217.26	219.82	215.88	219.30	5.72M
Jan 22, 2026	216.28	219.05	214.76	218.11	5.53M
Jan 21, 2026	212.47	218.00	211.57	216.15	10.7M
Jan 20, 2026	211.70	214.04	209.96	214.04	8.1M
Jan 16, 2026	215.61	217.35	213.88	214.35	7.86M
Jan 15, 2026	222.52	223.03	215.83	216.75	6.15M
Jan 14, 2026	221.00	223.34	217.00	221.89	7.71M
Jan 13, 2026	219.53	220.75	215.85	220.75	4.79M
Jan 12, 2026	221.19	222.49	218.39	220.04	6.55M
Jan 09, 2026	223.75	225.12	219.00	220.08	6.63M

Contact Details

North Chicago, IL 60064-6400

United States

https://www.abbvie.com 847 932 7900

About Company

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Beh�et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Stock Peers

LLY

37.34+3.66%

Eli Lilly and Company$1,058.18 JNJ

2.2+0.93%

Johnson & Johnson$239.99 NVS

2.47+1.60%

Novartis AG$156.42 MRK

2.18+1.82%

Merck & Co., Inc.$121.93 BMY

2.47+4.15%

Bristol-Myers Squibb Company$61.99 GSK

1.06+1.79%

GSK plc$60.23 NVO

4.3+9.92%

Novo Nordisk A/S$47.64 PFE

0.73+2.76%

Pfizer Inc.$27.22 OGN

0.11+1.36%

Organon & Co.$8.21 SRXH

-0.0029-2.25%

SRx Health Solutions Inc.$0.13

Company Overview

AbbVie Inc. (NYSE:ABBV) closed at $223.43 USD, gaining $4.41 (2.01%) from the previous close of $219.02. The stock is currently mid-range between its 52-week high and low $164.39 and $244.81. With a market capitalization of about $394.89 billion, AbbVie Inc. is classified as a mega-cap and shows lower-than-market volatility (beta ~0.33). Key stats such as the average daily volume over the past year has been around 6.41 million shares, in line with its 52-week average. Headquartered in North Chicago, IL, AbbVie Inc. operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Robert A. Michael, the company employs approximately 55,000 people and listed since January 02, 2013. AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 1.58%, SMA50 -0.26%, SMA200 6.58%). The stock’s 14-day RSI is 51.87 (neutral), while the ATR of 6.55 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -8.73% below its high and over 35.91% above its low. Average 10-day trading volume of 7.85 million shares is slightly above the 3-month average of 6.17 million, indicating heightened recent market interest.

Valuation Metrics

AbbVie Inc. trades at a P/E ratio of 94.46, slightly above the S&P 500 average, with a price-to-sales ratio of 6.48 and a price-to-book ratio of -151.09 indicating negative book value, which may reflect financial stress. The P/FCF stands at 28.69, also above market averages.

Dividend & Fair Value

AbbVie Inc. last paid a dividend of 6.65 per share, this equals a trailing yield of roughly 3.54%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $216.44. This means the shares are trading near this model’s fair value.

Earnings & Analyst Outlook

AbbVie Inc. generated EPS of $2.37 over the past year. Five-year average earnings growth is -2.63%. Wall Street analysts project EPS growth of 21.15% annually over the next five years. The latest quarter delivered EPS of $1.86. The next quarter is forecast at $3.01. Next year's EPS is expected at -$0.11. Analyst sentiment is bullish. Analyst rating data shows there are 17 Strong Buy ratings, 4 Buy ratings, 8 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $289.00 to $194.00. The high target offers 29.35% upside. The low target suggests -13.17% downside. The mean target is $244.21. This offers 9.3% upside. AbbVie Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended October 31, 2025, missed forecasts by 5.08%. The prior quarter beat by 3.13%. Over the last six quarters, Apple has recorded several small beats. These include 3.11% in July 25, 2024.

Shareholding & Insider Activity

AbbVie Inc. has 1.77 billion shares outstanding. The public float is 1.76 billion shares, elevated short interest at 1.25% of float. This equals 22.04 million shares. The short ratio is 3.53 days. Institutional investors hold 75.29% of the float. Insiders own 0.1%. GONZALEZ RICHARD A holds 388.93 thousand shares, Schumacher Laura J has 213.00 thousand shares and SALEKI-GERHARDT AZITA has 177.29 thousand shares. Over the past six months, insider transactions show net selling. They sold 42.37 thousand shares across 1 transactions.

Financial & Profitability Overview

Over the trailing twelve months, AbbVie generated $54.32B in revenue, or $30.64 per share. Gross margin was 83.84%, operating margin 32.08%, and net profit margin 8.95%. Returns are modest, with ROA at 3.61% and ROE at 46.94%.
On valuation metrics, AbbVie trades at a P/E of 94.46, P/S of 6.48 and P/B of -151.09. Liquidity is tight, with a current ratio of 0.72 and quick ratio of 0.60. Operationally, the company’s inventory turnover is 3.30 and cash conversion cycle is -559.97 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -26.02, supported by a cash flow-to-debt ratio of 0.20.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, AbbVie posted revenue of $54.32B, down slightly from $58.05B in the prior quarter. Gross profit was $45.54B (margin 83.84%). Operating income was $17.43B (margin 32.1%). Net income was$4.86B (EPS $2.73).
The company ended the quarter with $12.82B in cash and short-term investments, a total debt of $59.39B, and net debt of $46.57B. Total assets were $134.71B, with equity of $10.40B. Financials further reflected stability, with operating cash flow of $22.84B, free cash flow of $22.06B, and capital expenditures of - $777.00M.

Price Forecast & Outlook

Our AI price prediction model suggests that AbbVie Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.4%, with price expected at $226.55 by February 19, 2026, within a range of $222.00 to $231.29 3-Month Outlook: Projected rise of 6.44%, reaching $237.83 by May 06, 2026, with a range of $233.14 to $242.15. 1-Year Outlook: Projected gain of 11.27%, with price at $248.60 by February 05, 2027, within a range of $244.14 to $253.77.

Key Takeaways

AbbVie Inc. (NYSE:ABBV) shares are flat -6.32% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows AbbVie Inc. trading at a premium to the broader market with a P/E of 94.46. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $199.78, suggesting -10.58% downside. Our AI forecast model points to short-term strength (1.4% over two weeks), a medium-term rise (6.44% over three months), and a longer-term gain (11.27% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current AbbVie Inc. (ABBV) stock price?

AbbVie Inc. (NYSE: ABBV) stock price is $223.43 in the last trading session. During the trading session, ABBV stock reached the peak price of $225.82 while $218.50 was the lowest point it dropped to. The percentage change in ABBV stock occurred in the recent session was 2.01% while the dollar amount for the price change in ABBV stock was $4.41.

ABBV's industry and sector of operation?

The NYSE listed ABBV is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. AbbVie Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ABBV?

Mr. Jeffrey Ryan Stewart
Executive Vice President & Chief Commercial Officer
Mr. Scott T. Reents
Executive Vice President & Chief Financial Officer
Mr. Richard A. Gonzalez
Chairman & Chief Executive Officer
Dr. Thomas J. Hudson
Senior Vice President of R&D and Chief Scientific Officer
Mr. Perry C. Siatis
Executive Vice President, Gen. Counsel & Sec.
Mr. Timothy J. Richmond
Executive Vice President & Chief HR Officer
Dr. Nicholas R. Donoghoe M.D.
Executive Vice President and Chief Bus. & Strategy Officer
Dr. Azita Saleki-Gerhardt Ph.D.
Executive Vice President & Chief Operating Officer
Ms. Rae L. Livingston
Chief Equity Officer
Ms. Laura J. Schumacher
Vice Chairman of External Affairs & Chief Legal Officer
Dr. Thomas J. Hudson M.D.
Senior Vice President of R&D and Chief Scientific Officer
Ms. Tracie Haas
Senior Vice President of Corporation Responsibility, Brand & Communications
Dr. Thomas Hudson M.D.
Senior Vice President of R&D and Chief Scientific Officer
Ms. Carrie C. Strom
Senior Vice President of AbbVie & Pres of Global Allergan Aesthetics
Mr. Henry O. Gosebruch
Executive Vice President & Chief Strategy Officer
Mr. Robert A. Michael
Pres & Chief Operating Officer
Ms. Elizabeth Shea
Vice President of Investor Relations

How ABBV did perform over past 52-week?

ABBV's closing price is 35.91% higher than its 52-week low of $164.39 where as its distance from 52-week high of $244.81 is -8.73%.

How many employees does ABBV have?

Number of ABBV employees currently stands at 55,000.

Link for ABBV official website?

Official Website of ABBV is: https://www.abbvie.com

How do I contact ABBV?

ABBV could be contacted at phone 847 932 7900 and can also be accessed through its website. ABBV operates from 1 North Waukegan Road, North Chicago, IL 60064-6400, United States.

How many shares of ABBV are traded daily?

ABBV stock volume for the day was 5.05M shares. The average number of ABBV shares traded daily for last 3 months was 6.41M.

What is the market cap of ABBV currently?

The market value of ABBV currently stands at $394.89B with its latest stock price at $223.43 and 1.77B of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	55000
Beta	0.35
Sales or Revenue	$54.32B
5Y Sales Change%	0.445%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - General

ABBV Company Profile and Key Details

AbbVie

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Valuation Metrics

Key Takeaways